Edgeline Holdings, Inc. (ELHI.OB) Agrees to Terms for an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment
Edgeline Holdings, Inc. (ELHI.OB) Agrees to Terms for an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment Edgeline Holdings, Inc. (ELHI.OB), a biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies, recently announced that the company has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment. This technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents. Due to…